Xponance Inc. Cuts Stake in DaVita Inc. (NYSE:DVA)

Xponance Inc. cut its holdings in shares of DaVita Inc. (NYSE:DVA) by 6.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,907 shares of the company’s stock after selling 750 shares during the quarter. Xponance Inc.’s holdings in DaVita were worth $1,631,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DVA. SBI Securities Co. Ltd. acquired a new position in DaVita during the fourth quarter worth about $41,000. Quarry LP acquired a new position in DaVita during the third quarter worth about $60,000. Venturi Wealth Management LLC boosted its position in DaVita by 59.8% during the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company’s stock worth $61,000 after acquiring an additional 152 shares during the last quarter. Versant Capital Management Inc boosted its position in DaVita by 58.7% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $68,000 after acquiring an additional 169 shares during the last quarter. Finally, Blue Trust Inc. boosted its position in DaVita by 39.7% during the fourth quarter. Blue Trust Inc. now owns 461 shares of the company’s stock worth $76,000 after acquiring an additional 131 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on DVA. Cowen restated a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. StockNews.com lowered shares of DaVita from a “buy” rating to a “hold” rating in a report on Friday. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a report on Friday, February 21st. Finally, Barclays boosted their target price on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $166.33.

DaVita Price Performance

DaVita stock opened at $148.25 on Friday. The company’s 50 day simple moving average is $158.53 and its 200-day simple moving average is $157.51. The company has a market capitalization of $11.86 billion, a price-to-earnings ratio of 13.80, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99. DaVita Inc. has a 1 year low of $125.64 and a 1 year high of $179.60. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26.

DaVita (NYSE:DVA) last released its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. As a group, equities research analysts expect that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.